Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

Background: Programmed cell death protein 1 (PD1) inhibitors have revolutionized cancer therapy, yet many patients fail to respond. Thus, the identification of accurate predictive biomarkers of therapy response will improve the clinical benefit of anti-PD1 therapy. Method: We assessed the baseline s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Qiaoyun, Wang, Dan, Yang, Jianliang, Xing, Puyuan, Yang, Sheng, Li, Yang, Qin, Yan, He, Xiaohui, Liu, Yutao, Zhou, Shengyu, Duan, Hu, Liang, Te, Wang, Haoyu, Wang, Yanrong, Jiang, Shiyu, Zhao, Fengyi, Zhong, Qiaofeng, Zhou, Yu, Wang, Shasha, Dai, Jiayu, Yao, Jiarui, Wu, Di, Zhang, Zhishang, Sun, Yan, Han, Xiaohong, Yu, Xiaobo, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255026/
https://www.ncbi.nlm.nih.gov/pubmed/32483460
http://dx.doi.org/10.7150/thno.45816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255026/
https://www.ncbi.nlm.nih.gov/pubmed/32483460
http://dx.doi.org/10.7150/thno.45816

Ejemplares similares